Renovorx, INC Form 4 insider transactions

RenovoRx, Inc.'s Chief Clinical Officer, Leesa Gentry, was granted 6,619 stock options with an exercise price of $1.27, vesting over four years.

RenovoRx, Inc. has granted 41,600 incentive stock options to Ron Kocak, VP, Controller and PAO, under its 2021 Omnibus Equity Incentive Plan, with vesting commencing January 1, 2025.

RenovoRx, Inc.'s Chief Medical Officer and Director, Ramtin Agah, reported an open market purchase of 21,000 shares of common stock on June 5, 2025, increasing his beneficial ownership to 734,460 shares.

Ramtin Agah, Chief Medical Officer and Director of RenovoRx, Inc., reported a gift of 400,000 shares of common stock to trusts for his children, reducing his direct beneficial ownership.

Laurence Marton, a director of RenovoRx, Inc., exercised stock options to acquire 20,480 shares of common stock at $0.15 per share on May 2, 2025.

Ramtin Agah, Chief Medical Officer of RenovoRx, Inc., recently purchased 15,000 shares of common stock in the open market.

RenovoRx CEO Shaun Bagai was granted stock options to purchase 409,992 shares of the company's common stock, vesting over four years.

Leesa Gentry, Chief Clinical Officer of RenovoRx, Inc., was granted stock options to purchase 26,477 shares of the company's common stock on April 14, 2025.

Ron Kocak, VP, Controller and PAO of RenovoRx, Inc., was granted incentive stock options to purchase 166,400 shares of the company's common stock on April 14, 2025.

Ramtin Agah, Chief Medical Officer of RenovoRx, Inc., was granted stock options to purchase 254,542 shares of the company's common stock.

RenovoRx CEO Shaun Bagai reports purchasing 7,500 shares of common stock at $0.9095 per share.

Ramtin Agah, Chief Medical Officer of RenovoRx, Inc., purchased 20,000 shares of common stock at $0.80 per share.

Ron Kocak, VP Controller and PAO of RenovoRx, Inc., reports open market purchases of RNXT common stock between April 8th and April 10th, 2025.

Ramtin Agah, Chief Medical Officer of RenovoRx, Inc., recently purchased 30,000 shares of the company's common stock at an average price of $0.8133 per share.

RenovoRx CEO Shaun Bagai reports purchasing 10,000 shares of common stock at an average price of $0.83.

Director Laurence Marton increased his holdings in RenovoRx, Inc. (RNXT) through an open market purchase of 12,050 shares at $0.848 per share.

Ramtin Agah, Chief Medical Officer of RenovoRx, Inc., reports purchasing 26,000 shares of common stock in the open market.

RenovoRx CEO Shaun Bagai reports purchasing 10,000 shares of RNXT common stock at an average price of $0.83.

Director Una S. Ryan acquired 25,099 stock options in RenovoRx, Inc. on October 1, 2024, according to a Form 4 filing.

Director Macfarlane K. Angela reports acquisition of stock options in RenovoRx, Inc.

Director Laurence Marton acquired 25,099 stock options in RenovoRx, Inc. on October 1, 2024.

Robert J. Spiegel, a director of RenovoRx, Inc., acquired 25,099 stock options on October 1, 2024, according to a Form 4 filing with the SEC.

Chief Clinical Officer Leesa Gentry acquired 190,000 incentive stock options in RenovoRx, Inc. on March 6, 2024.